uniQure initiated with a Buy at B. Riley FBR. B. Riley FBR analyst Madhu Kumar started uniQure with a Buy rating and $50 price target. The company could dominate hemophilia B adeno-associated viral gene therapy, Kumar tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.